Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Platelet-activating factor (PAF) antagonism and improved microcirculatory rheology

PAF Antagonism & Microvascular Hemorheology · Vascular endothelium and hemodynamics

Specifically occupies the platelet-activating factor (PAF) receptor, blocking platelet adhesion, aggregation and microthrombus formation. It also improves red blood cell deformability and lowers abnormal capillary permeability.

Why it matters: A core pharmacological target for improving deep-brain microvascular perfusion, inner ear microcirculation (tinnitus/vertigo) and microcirculatory flow resistance problems in the extremities.

Molecular targets: PAF receptor (PTAFR), Red blood cell deformability, Relief of microvascular spasm, Local free radical scavenging

Supplements acting on this mechanism (ranked by strength and evidence)

Lumbrokinase

★★★☆☆Mechanism evidence: grade A

In one multicenter study, some patients’ blood and plasma viscosity measures may have improved. This is a change in hemorheology. It does not show that lumbrokinase antagonizes the PAF receptor, and there is currently no evidence that it specifically occupies PAF receptors in humans.

Micronized purified flavonoid fraction

★★☆☆☆Mechanism evidence: grade B

A small human study observed that micronized flavonoids can increase red blood cell velocity in ankle capillaries, and improved capillary permeability has been reported. These results do not prove PAF receptor antagonism, and claims about leukocyte adhesion and ICAM-1 also lack human evidence.

Standardized Ginkgo biloba leaf extract (EGb 761)

★☆☆☆☆Mechanism evidence: grade D

Ginkgolides can antagonize platelet-activating factor (PAF) in vitro and inhibit the platelet aggregation it induces. However, at standard EGb 761 doses, peak blood levels after oral dosing are far below the concentrations needed in vitro, so results from high-dose pure ginkgolides cannot be directly extrapolated.

Rutin / troxerutin

★☆☆☆☆Mechanism evidence: grade D

In-vitro experiments on rabbit platelets showed that rutin, at concentrations of tens to hundreds of micromolar, can inhibit PAF-induced calcium responses. These concentrations are far above the exposure to unconjugated parent drug normally seen after oral dosing, and receptor-specific occupancy has not been demonstrated, so these results cannot currently be taken as evidence of an antiplatelet effect in humans.

Open in the interactive app ›